StockData

Eloxx Pharmaceuticals vs Relay Therapeutics

ELOX and RLAY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ELOX and RLAY compare

Relay Therapeutics is the larger company, worth 75 times as much as Eloxx Pharmaceuticals ($4.0B against $53.1M).

Relay Therapeutics grew revenue faster over the last twelve months (23.9% versus −100% for Eloxx Pharmaceuticals).

Relay Therapeutics scores higher on the StockData Score (10 against 7 for Eloxx Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricELOXRLAY
Size and price
Market cap$53.1M$4.0B
Share price$13.15$18.09
Change, 1 year1195350%193%
Change, 5 years−97.8%−47.5%
Beta (5Y)–1.94
Employees7192
StockData Score
Total score710 (better)
Valuation score1 (better)0
Growth score02 (better)
Performance score12 (better)
Health score56 (better)
Dividend score00
Valuation
P/S–383×
P/B1.1× (better)4.8×
Growth
Revenue growth (TTM)−100%23.9% (better)
Revenue growth, 5Y average–−28.6%
Profitability
Operating margin–−3095%
Net margin–−2837%
Return on equity−54.3%−41.2% (better)
Return on invested capital–−41.8%
Financial health
Debt / equity0.000.00
Current ratio3.7414.62 (better)
Altman Z-score−4.4025.18 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions71.8%113%
Held by insiders42.6%24.5%
Insider net buying, 12 months–−$129M
Superinvestors holding–1
Short interest, % of float2.3%26.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.